Prothena Corporation plc

Prothena Corporation plc

PRTA · Nasdaq

Prothena Corporation plc (PRTA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Prothena Corporation plc in 2026. The next earnings report is expected on October 29, 2026.

Earnings calendar

Next earnings date

29 Oct 2026

In 71 days

EPS estimate

-0.22

Revenue estimate

9.6M

Past earnings

06 Aug 2026
EPS actual
-0.36 (+7.7%)
estimate -0.39
Revenue actual
1.0M (+139.5%)
estimate 421.7K
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
07 May 2026
EPS actual
0.60 (+272.2%)
estimate -0.35
Revenue actual
51.1M (+6,215.2%)
estimate 808.9K
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
19 Feb 2026
EPS actual
-0.40 (+28.4%)
estimate -0.56
Revenue actual
21.0K (-98.4%)
estimate 1.3M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
06 Nov 2025
EPS actual
-0.68 (+1.0%)
estimate -0.69
Revenue actual
2.4M (-63.6%)
estimate 6.6M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Prothena Corporation plc beat consensus estimates in its latest earnings report, with EPS of $-0.36 versus an estimate of $-0.39 and revenue of $1.01 million exceeding the $421.67 thousand estimate by 139.5%. In the prior report both EPS and revenue were also ahead of expectations.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Sector
Healthcare
Industry
Biotechnology
Country
Ireland
Exchange
Nasdaq
CEO
Gene G. Kinney
Employees
163
IPO date
18 Dec 2012
ISIN
IE00B91XRN20
Website
prothena.com

Frequently asked questions

When does Prothena Corporation plc (PRTA) next report earnings?

Prothena Corporation plc (PRTA) is scheduled to report earnings on October 29, 2026.

What was Prothena Corporation plc's most recent earnings date?

Prothena Corporation plc (PRTA) last reported earnings on August 6, 2026.

Where is Prothena Corporation plc stock listed?

Prothena Corporation plc (PRTA) is listed on Nasdaq.